Jun 28, 2016 - An API 5000 tandem ... radiograph were done in most of patients. ... criteria to evaluate the difference in results obtained and graph them on a.
Pediatric/Fetal Clinical Chemistry
Wednesday, August 3, 2016 Poster Session: 9:30 AM ‑ 5:00 PM Pediatric/Fetal Clinical Chemistry
B-220 Evaluation of GDF-15 and YKL-40 as Early Markers of Subclinical Diabetic Nephropathy and Cardiovascular Morbidity in Young Patients with Type 1 Diabetes Mellitus I. Papassotiriou1, N. Papadopoulou-Marketou2, C. Skevaki3, I. Kosteria4, G. Chrousos4, C. Kanaka-Gantenbein4. 1Department of Clinical Biochemistry, “Aghia Sophia” Children’s Hospital, Athens, Greece, 2Department of Endocrinology, Department of Medical Health, Linköping University, Linköping, Sweden, 3Institute for Laboratory Medicine, Pathobiochemistry and Molecular Diagnostics, Philipps University of Marburg, Marburg, Germany, 4First Department of Pediatrics, University of Athens Medical School, “Aghia Sophia” Children’s Hospital, Athens, Greece Background: Diabetic nephropathy constitutes a major long-term complication in patients with type 1 diabetes mellitus (T1DM) and its diagnosis is based on microalbuminuria. Growth Differentiation Factor-15 (GDF-15) is a protein belonging to the transforming growth factor beta superfamily that has a role in regulating inflammatory and apoptotic pathways in injured tissues and during disease processes. Chitinase-3-Like Protein 1 (YKL-40) is a protein with the ability to communicate with other signal transduction pathways to modulate various physiologic processes, such as inflammation, apoptosis, tissue remodeling, cell growth, and angiogenesis. An increasing body of evidence exists supporting the involvement of these two proteins GDF-15 and YKL-40 in cardio-renal events, therefore we aimed to investigate in an observational follow-up study their role in unravelling early diabetic nephropathy and their impact as potential risk markers for cardiovascular morbidity. Patients and Methods: Fifty-six patients with T1DM, aged 13.1±3.2 years and 49 healthy controls aged 12.8±6.6 years were recruited. Along with standard blood and urine chemistry, measurements of serum Neutrophil Gelatinase Associated Lipocalin (NGAL), Cystatin C, YKL-40 and GDF-15 were performed by means of immunoenzymatic and immunonephelometric techniques. eGFR values were calculated from Cystatin C based e-GFR equations1. The measurements were performed at enrolment and after 12-15 months. Results: At baseline, mean GDF-15 levels were not significantly different between children with diabetes (289.5pg/mL) and controls (278.6pg/ml). At re-evaluation, mean GDF-15 in patients increased (366.7pg/mL), (p=0.001) and was significantly higher than in controls (p
